In contrast, AML cells generated from bone marrow progenitors of Trp53-deficient mice showed hypersensitivity to decitabine, which implies that long-term chronic inhibition of p53 function gradually increases sensitivity of AML cells to decitabine through secondary genetic and/or epigenetic changes. This evidence concerns the gene TP53 and acute myeloid leukemia.